Xenon Pharmaceuticals Inc. (XENE): Operating Cash Flow
-$279.12M
Year ended 2025-12-31
-$337.52M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$279.12M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$181.39M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$151.11M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$101.03M | n/c | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | -$69.50M | n/m | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | -$48.12M | n/m | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | -$4.71M | n/c | 2021-03-01, From 2019-01-01 |
| 2018-12-31 | -$34.72M | n/m | 2020-03-09, From 2018-01-01 |
| 2017-12-31 | -$28.73M | n/m | 2019-03-06, From 2017-01-01 |
| 2016-12-31 | -$19.57M | n/m | 2018-03-07, From 2016-01-01 |
| 2015-12-31 | -$18.10M | n/m | 2018-03-07, From 2015-01-01 |
| 2014-12-31 | $266.0K | n/m | 2017-03-08, From 2014-01-01 |
| 2013-12-31 | -$3.32M | n/m | 2016-03-08, From 2013-01-01 |
| 2012-12-31 | $45.57M | n/a | 2015-03-12, From 2012-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | -$279.12M | n/m |
| Adagene Inc. (ADAG) | 2025-12-31 | -$15.66M | n/m |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | -$39.85M | n/m |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | -$38.33M | n/m |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | -$47.11M | n/m |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | -$97.43M | n/m |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | -$10.74M | n/m |
| Immunome Inc. (IMNM) | 2025-12-31 | -$190.92M | n/m |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | -$750.35M | n/m |
Compare XENE, ADAG, BOLT, OVID side by side · Screen every company in Pharmaceutical Preparations ↗